A direct head-to-head comparison of every published human trial for NMN and NR — evidence rated honestly, and what the first head-to-head trial will tell us.
NAD+ declines with age. That much is established. Whether supplementing with its precursors meaningfully reverses that decline in humans — and whether that reversal translates to clinical benefit — is the open question.
Nicotinamide mononucleotide (NMN) and nicotinamide riboside (NR) are both oral NAD+ precursors. Both raise NAD+ levels in human blood. Both have been studied in randomised controlled trials. Neither has demonstrated hard clinical longevity outcomes in humans. The evidence base for each is Emerging — meaning a signal exists but is insufficient for clinical confidence.
The supplement market treats NMN and NR as near-equivalent, distinguished mainly by price and marketing. The evidence base suggests they are different compounds with different pharmacokinetics, different cellular uptake mechanisms, and potentially different efficacy profiles — though no trial has directly compared them until recently.
| Dimension | NMN | NR |
|---|---|---|
| Published RCTs | 4 | 3 |
| Evidence tier | Emerging | Emerging |
| NAD+ elevation | Consistent across trials | Consistent across trials |
| Clinical outcomes | Modest functional signals | Modest CV signals |
| Bioavailability | Debated; direct vs indirect pathway | Well-characterised oral bioavailability |
| Dose studied | 250–600mg/day | 500–1000mg/day |
| Longest RCT | 12 weeks | 12 weeks |
| Hard longevity endpoints | None | None |
| Head-to-head data | Ongoing trial | Ongoing trial |
Both NMN and NR reliably raise NAD+ levels in human blood. What that means clinically is not established. The trials to date are small, short, and have used surrogate endpoints — NAD+ levels, physical function, cardiovascular markers — rather than hard longevity outcomes.
Neither compound has demonstrated lifespan extension, reduction in age-related disease incidence, or any other hard longevity outcome in humans. The evidence tier for both is Emerging — meaning a biological signal exists and warrants continued investigation, but is not sufficient for clinical confidence.
The first head-to-head NMN vs NR trial, registered in 2026 with results expected in 2027, will provide the first direct comparative data. Until those results are available, selecting one over the other based on published evidence alone is not possible. Geroevidence will update both profiles immediately upon publication.